Abstract:Genome editing tools, particularly the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems (e.g., CRISPR/Cas9), and their repurposing into epigenetic editing platforms, offer enormous potential as safe and customizable therapies for cancer. Specifically, various transcriptional abnormalities in human malignancies, such as silencing of tumor suppressors and ectopic re-expression of oncogenes, have been successfully targeted with virtually no off-target effects using CRISPR activation and repression systems. In these systems, the nuclease-deactivated Cas9 protein (dCas9) is fused to one or more domains inducing selective activation or repression of the targeted genes. Despite these advances, the efficient in vivo delivery of these molecules into the target cancer cells represents a critical barrier to accomplishing translation into a clinical therapy setting for cancer. Major obstacles include the large size of dCas9 fusion proteins, the necessity of multimodal delivery of protein and gRNAs, and the potential of these formulations to elicit detrimental immune responses.In this context, viral methods for delivering CRISPR face several limitations, such as the packaging capacity of the viral genome, the potential for integration of the nucleic acids into the host cells genome, and immunogenicity of viral proteins, posing serious safety concerns. The rapid development of mRNA vaccines in response to the COVID-19 pandemic has rekindled interest in mRNA-based approaches for CRISPR/dCas9 delivery. Simultaneously, due to their high loading capacity, scalability, customizable surface modification for cell targeting, and low immunogenicity, lipid nanoparticles (LNPs) have been widely explored as nonviral vectors. In this chapter, we first describe the design of optimized dCas9-effector mRNAs and gRNAs for epigenetic editing. We outline formulations of LNPs suitable for dCas9 mRNA delivery. Additionally, we provide a protocol for the co-encapsulation of the dCas9-effector mRNAs and gRNA into these LNPs, along with detailed methods for delivering these formulations to both cell lines (in vitro) and mouse models of breast cancer (in vivo).

Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment

Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy

Harnessing the evolving CRISPR/Cas9 for precision oncology

Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer Immunotherapy

CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy

The Potential Revolution of Cancer Treatment with CRISPR Technology

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy

A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Thermo-Triggered Release Of Crispr-Cas9 System By Lipid-Encapsulated Gold Nanoparticles For Tumor Therapy

Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy

Strategies for organic nanoparticles delivering CRISPR/Cas9 for cancer therapy: Challenges and breakthroughs

Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA

CRISPR-Cas9 in basic and translational aspects of cancer therapy

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy